Direxion Daily Financial Bull 3X Shares ETF
FAS
Spdr S&P Bank Etf
KBE
Ultra Financials Proshares
UYG
4
SPDR S&P Metals & Mining ETF
XME
5
SPDR S&P Retail ETF
XRT
US Stock MarketDetailed Quotes
Cellectis (CLLS)
- 4.060
- -0.730-15.24%
Close Dec 16 16:00 ET
- 4.060
- 0.0000.00%
Post 20:01 ET
407.32MMarket Cap-12.30P/E (TTM)
4.260High3.910Low148.07KVolume4.250Open4.790Prev Close601.92KTurnover0.21%Turnover RatioLossP/E (Static)100.33MShares5.48052wk High4.05P/B285.38MFloat Cap1.10052wk Low--Dividend TTM70.29MShs Float50.000Historical High--Div Yield TTM7.31%Range %0.963Historical Low4.065Avg Price1Lot Size
CLLS Stock Chart
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
CLLS Orderflow
Unit: --
CLLS Orderflow Trend
IntradayDayWeekMonth
No Data
Cellectis (CLLS) News
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday
Express News | Cellectis Shares Are Trading Lower After Arbitration Ruled in Favor of Allogene in Relation to Cemacabtagene Ansegedleucel
Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Allogene Therapeutics Reports Result for Servier In Arbitration With Cellectis; Arbitration Ruling Reaffirms Allogene's Full Control of Cemacabtagene Ansegedleucel; Decision Reconfirms Allogene's Expanded Sub-License Covering EU And UK Rights With...
3 European Penny Stocks With Market Caps Under €400M
Express News | Cellectis Shares Updated Eti-Cel Phase 1 Data At ASH 2025 In R/r NHL, With IL-2 Support Cohort Enrollment Starting Q1 2026
Cellectis (CLLS) Stock Forum
$Cellectis (CLLS.US)$
Cellectis Announces Arbitral Decision in Dispute with Servier
Monday, 15th December at 4:51 pm
NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announces that the Arbitral Tribunal has issued its decision in the arbitration proceedings against Les Laboratoires Servier and Institut de Recherches Internation...
Cellectis Announces Arbitral Decision in Dispute with Servier
Monday, 15th December at 4:51 pm
NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announces that the Arbitral Tribunal has issued its decision in the arbitration proceedings against Les Laboratoires Servier and Institut de Recherches Internation...
1
$Cellectis (CLLS.US)$ Moligo Technologies and Cellectis Demonstrate Potential of Enzymatic Single-Stranded DNA for Non-Viral Gene Editing in Nature Communications
PR Newswire
1m
Nature Communications article shows highly efficient and scalable gene insertion of long, single-stranded DNA donor templates in hematopoietic stem cells
STOCKHOLM, Nov. 21, 2025 /PRNewswire/ -- Moligo Technologies, a DNA synthesis company advancing gene therapies, announced today the publication of an article in Nat...
PR Newswire
1m
Nature Communications article shows highly efficient and scalable gene insertion of long, single-stranded DNA donor templates in hematopoietic stem cells
STOCKHOLM, Nov. 21, 2025 /PRNewswire/ -- Moligo Technologies, a DNA synthesis company advancing gene therapies, announced today the publication of an article in Nat...
1
$Cellectis (CLLS.US)$
Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting
Monday, 28th April at 4:30 pm
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today unveils research data on TALEN®-mediated non-viral transgene insertion for advancing cellular and gene therapies, and advan...
Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting
Monday, 28th April at 4:30 pm
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today unveils research data on TALEN®-mediated non-viral transgene insertion for advancing cellular and gene therapies, and advan...
2
$Cellectis (CLLS.US)$ let’s go 🚀🚀🚀🚀
1
$Cellectis (CLLS.US)$ going to 2
1
1
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)